Table 4: Select endogenous growth factors and their known functions in fracture healing.
Growth factorsa | Known role in fracture healing | Produced by | Acts upon | Common orthopaedic uses |
---|---|---|---|---|
PDGF |
Recruits inflammatory cells to fracture site. Increases cellular proliferation and collagen deposition. Promotes angiogenesis29 |
Platelets, monocytes, endothelial cells |
signal mechanism involves tyrosine kinase receptors |
|
TGF-β |
May regulate cartilage and bone formation in fracture callus through stimulation of collagen and proteoglycans production by mesenchymal cells. |
Platelets, osteoblasts, chondrocytes |
signal mechanism involves serine/threonine kinase receptors |
Used to augment porous-coated implants; BMP-2 and -7 (member of TGF- β family commonly used in lumbar fusions, fracture nonunions, open tibia fractures) |
VEGF |
Promotes vasculogenesis and angiogenesis |
Platelets, chondrocytes in callus |
Vascular endothelial cells |
|
FGF |
Increase cellular division and collagen deposition. Promotes angiogenesis. |
|
|
|
PTH |
Promotes bone deposition when used in pulsatile fashion. May have osteoinductive properties.24 |
Parathyroid glands |
Mesenchymal stem cells24 |
rhPTH (teriparatide) has been shown to increase bone mineral density lumbar spines and femoral necks. Reduces overall fracture risk. |
ILGF | The primary mediator of human growth hormone; functions in growth of many cell types Induces linear skeletal growth by promoting cellular proliferation without maturation (physeal closure). Supports anabolic muscle and bone growth in mature skeleton. |
Osteoblasts, chondrocytes, hepatocytes | Many cell types, various insulin/IGF-1 receptors | FDA approved for use in pediatric treatment of short stature from growth hormone insensitivity (GHI) 30 |
a PDGF, platelet-derived growth factor; TGF-β, transforming growth factor beta; VEGF, vascular endothelial growth factor; FGF, fibroblast growth factor; rhPTH, recombinant human parathyroid hormone; ILGF, insulin-like growth factor